Business Wire

DAWEX

26.3.2020 22:54:08 CET | Business Wire | Press release

Share
COVID-19 Data Exchange to Curb the Virus’ Propagation and Limit Its Economic Impact

Under the impulsion of the World Health Organization and the European Union stressing the importance of data sharing, Dawex , the leading data exchange technology company, today announced launching a COVID-19 Data Exchange initiative. The platform will be available pro bono to a large community of companies and organizations looking to contribute to the resolution of this crisis. The technology enables the exchange of vital non-personal data to hinder COVID-19’s dissemination and restrain its economic impact.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200326005767/en/

Scientific communities, hospitals and healthcare operations, pharmaceutical organizations, retailers, transport & logistics companies, specialized equipment manufacturers and distributors, consulting organizations, technology companies and health tech startups, banks, insurance, global and regional health organizations, governmental agencies, municipalities and other public services will be able to securely and easily access, publish, and exchange multiple sources of non-personal data worldwide, therefore acquiring more capabilities to answer crisis-related complex questions, faster.

“There is an unparalleled demonstration of solidarity from many organizations to contribute to the resolution of this crisis. It was an evidence for Dawex to immediately engage its resources and technology to bring the best environment to all these organizations to exchange data in the best conditions,” says Laurent Lafaye, co-founder and co-CEO of Dawex.

Join worldwide and regional organizations in this endeavour and proactively exchange critical non-personal data to contribute to stopping the virus’ progression and its economic impact. Get involved now

By using COVID-19 Data Exchange, participants remain in full control of the data they share, decide with whom they share it, and keep track of all data flows. Only vetted participants from public and private organizations will be granted access to the COVID-19 Data Exchange to ensure confidentiality and relevance of the data exchanges.

“COVID-19 crisis is challenging the way we will use data in the future. Thousands of data providers are willing to share their sources of data, right now, for free. Without trust, fairness and use cases, this effort will be pointless. Our dedicated team of experts from Deloitte, in data management, healthcare and artificial intelligence will make the most out of this coalition and Dawex technology,” says Mathieu Colas, Senior Partner at Deloitte.

“The COVID-19 Data Exchange will facilitate and accelerate data exchanges while we are in the midst of the storm. Moreover, it brings the community together, strengthening our ability to respond to future crises and prepare for a better and stronger future,” says Fabrice Tocco, co-founder and co-CEO of Dawex.

About Dawex

Dawex, a leading data exchange technology company, allows organizations to orchestrate data circulation by sourcing and exchanging data directly, securely and in full compliance with regulations. Today 10,000 organizations from 20+ sectors rely on Dawex Data Exchange solutions to build their data exchange strategy. Created in 2015, Dawex is an international company headquartered in France, and serving customers in more than 50 countries. www.dawex.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release

As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi

Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release

Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor

Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release

Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co

Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release

Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.

Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release

Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye